Ibramvibart clinical trials
Also written VYD2311.
How each study uses ibramvibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ibramvibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VYD2311
- 3
Studies by the year they started
4 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Invivyd, Inc. (4)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ibramvibart.
- Jun 2027Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromePhase 2 · Invivyd, Inc.
Studies
Open first, then newest update. How each study uses ibramvibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromeNot yet recruitingPhase 2Invivyd, Inc.NCT07899346Written as VYD2311
- Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineCompletedPhase 3Invivyd, Inc.NCT07655180Written as VYD2311
- Study of VYD2311 for the Prevention of COVID-19Active, not recruitingPhase 3Invivyd, Inc.NCT07298434Written as VYD2311-SD
- A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsActive, not recruitingPhase 1Invivyd, Inc.NCT06523153Written as VYD2311
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromeOct 27, 2026NCT07899346
Codes
What other systems call ibramvibart · ClinicalTrials.gg INT017606
- UNII (FDA) PRC4J48944IBRAMVIBARTOne source FDA
- NCI Thesaurus C215285IbramvibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PRC4J48944 | IBRAMVIBART | One source FDA |
| NCI Thesaurus | C215285 | Ibramvibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.